Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial

Neurology

Volumn 67, Issue 7, 2006, Pages 1262-1264

  Bender, A ^a   Koch, W ^a   Elstner, M ^a   Schombacher, Y ^a   Bender, J ^d   Moeschl, M ^a   Gekeler, F ^a   Muller Myhsok B ^b   Gasser, T ^c   Tatsch, K ^a   Klopstock, T ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; BROMOCRIPTINE; CABERGOLINE; CREATINE; CREATINE PHOSPHATE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

EID: 33749835508     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000238518.34389.12     Document Type: Article

References (10)

1. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999;157:142-149.
2. Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005;252:36-41.
3. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003;60:1234-1240.
4. Lyoo IK, Kong SW, Sung SM, et al. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 2003;123:87-100.
5. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004;19:1370-1374.
6. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005;10:900-919.
7. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-946.
8. Whone AL, Watts RL, Stoessl AJ, et al., REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
9. Ellis AC, Rosenfeld J. The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS Drugs 2004;18:967-980.
10. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.